Rare Breast Cancer Subtypes
- PMID: 33755810
- PMCID: PMC8204849
- DOI: 10.1007/s11912-021-01048-4
Rare Breast Cancer Subtypes
Abstract
Purpose of review: Breast cancer is a collection of diseases including the more common invasive ductal and lobular carcinomas and rarer subtypes of breast cancer. This review summarizes the features of rare breast cancers.
Recent findings: Each of the rare tumors has defined pathological and clinical features that impact treatment recommendations. In this review, we summarize these for each rare type of breast cancer and where available we include molecular features of each tumor. Rare subtypes of breast cancer each have unique features. In many cases, data is limited for the optimal treatment approaches.
Keywords: Breast cancer; Rare breast cancer subtypes.
Similar articles
-
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.Oncologist. 2014 Aug;19(8):805-13. doi: 10.1634/theoncologist.2014-0108. Epub 2014 Jun 26. Oncologist. 2014. PMID: 24969162 Free PMC article.
-
Influence of breast cancer histology on the relationship between ultrasound and pathology tumor size measurements.Mod Pathol. 2004 Aug;17(8):905-10. doi: 10.1038/modpathol.3800138. Mod Pathol. 2004. PMID: 15105809
-
The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.Breast Cancer. 2021 Jan;28(1):187-195. doi: 10.1007/s12282-020-01146-4. Epub 2020 Aug 18. Breast Cancer. 2021. PMID: 32812198
-
Histology and immunophenotype of invasive lobular breast cancer. daily practice and pitfalls.Breast Dis. 2008-2009;30:15-9. doi: 10.3233/BD-2009-0278. Breast Dis. 2008. PMID: 19850991 Review.
-
Neuroendocrine breast carcinoma: a rare but challenging entity.Med Oncol. 2020 Jul 25;37(8):70. doi: 10.1007/s12032-020-01396-4. Med Oncol. 2020. PMID: 32712767 Free PMC article. Review.
Cited by
-
Complex Role of Circulating Triglycerides in Breast Cancer Onset and Survival: Insights From Two-Sample Mendelian Randomization Study.Cancer Med. 2025 Feb;14(4):e70698. doi: 10.1002/cam4.70698. Cancer Med. 2025. PMID: 39960141 Free PMC article.
-
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane-PLD versus PLD-Taxane in Patients with Metastatic Breast Cancer.Cancers (Basel). 2023 Oct 12;15(20):4953. doi: 10.3390/cancers15204953. Cancers (Basel). 2023. PMID: 37894320 Free PMC article.
-
Secretory Breast Carcinoma: Report of Two Cases and Literature Review.Clin Med Insights Case Rep. 2023 Oct 31;16:11795476231209182. doi: 10.1177/11795476231209182. eCollection 2023. Clin Med Insights Case Rep. 2023. PMID: 37920370 Free PMC article.
-
Deep Learning-Based Recognition of Different Thyroid Cancer Categories Using Whole Frozen-Slide Images.Front Bioeng Biotechnol. 2022 Jul 6;10:857377. doi: 10.3389/fbioe.2022.857377. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35875502 Free PMC article.
-
Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer.Oncol Lett. 2024 Apr 10;27(6):260. doi: 10.3892/ol.2024.14393. eCollection 2024 Jun. Oncol Lett. 2024. PMID: 38646491 Free PMC article.
References
-
- Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350–60. - PubMed
-
- Sharpiro C, Barsky SH. Infiltrating carcinomas of the breast: Not one disease. In: Bland KI, Copeland, editors. The Breast: Comprehensive management of benign and malignant disease. 1. Philadelphia, PA: Saunders Elsevier; 2009. p. 231–47.
-
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.
This landmark paper identified molecular subtypes of breast cancer including luminal A, luminal B, basal and HER2 enriched based on the gene expression patterns, and is the basis for preclinical and clinical trial approaches to breast cancer.
-
-
-
WHO Classification of Tumours Editorial Board. Breast Tumours: World Health Organization classification of tumours. 5th ed. Lyon, France: IARC Press; 2019.
The WHO classification of breast cancer is the reference for all pathology analysis and classification.
-
-
- Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials